Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2000

View Archived Issues

Schering-Plough exercises option to novel interferon discovered by HGS

DeveloGen and HepaVec merge

Phase II data for Replagal show improvement in pain and renal function

Alexion's C5 inhibitor antibody 5G1.1 granted orphan drug status by FDA

Encouraging results from first clinical trials for Pompe's disease

Fabrazyme meets primary endpoint in pivotal trial of Fabry's disease

Researchers seek mechanism of potent, long-acting neuroprotective agent

Uncoupling protein in muscle blocks obesity in transgenic mice

Intensive PEG-L-asparaginase regimen improves remission rates in ALL

Proposed acquisition will strengthen Alliance's imaging agent pipeline

Pregabalin displays efficacy in anxiety disorders in clinical trials

Colostrum-derived polypeptide improves outcome in AD patients

Initial clinical results support further evaluation of GW-320659 in ADHD

U.K. authorities clear new ED treatment for launch

Market launch for Trisenox, a new Rx for a severe form of leukemia

Second gene therapy product from Collateral advances to clinical testing

Strategic collaboration aims to develop new cancer immunotherapies

Development of compound for diabetic neuropathy suspended by Pfizer based on safety data

SangStat obtains technology to develop smaller ciclosporin capsule

Novel 5-HT reuptake inhibitors specifically claimed for use in premature ejaculation

Preparation and use of new tachykinin antagonists disclosed by MS&D

Recently issued patent covers cholinergic amide compounds from Fujisawa

Boehringer Ingelheim synthesizes new series of tyrosine kinase inhibitors

Estrogenic agents designed by AHP for use in bone and cardiovascular disorders

New PGF analogues and their use in osteoporosis and glaucoma

Chemokine receptor-modulating pyrrolidine compounds in the Merck pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...